Session » SLE – Etiology & Pathogenesis Poster (1480–1506)

Date: Tuesday, November 9, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 1496

A Metagenome-wide Association Study Revealed Disease-specific Landscape of the Gut Microbiome of Systemic Lupus Erythematosus in Japanese

8:30AM-10:30AM: Abstract Number: 1486

A Novel Requirement for IFNβ1 Signaling for IFNκ Induction in Keratinocytes

8:30AM-10:30AM: Abstract Number: 1492

A Permissive Factor of Anti-Ro+ Mothers of Neonatal Lupus Children Is Linked to Overt SLE Associated with Immunity to a Gut Commensal

8:30AM-10:30AM: Abstract Number: 1504

Association Between Anti-RNP Antibodies and Interferon Gene Expression but Not Complement Consumption in SLE

8:30AM-10:30AM: Abstract Number: 1493

Association of the Soluble Terminal Complement Complex C5b-9 (sC5b-9) with Urinary Signs of Kidney Disease in a Swiss SLE Cohort

8:30AM-10:30AM: Abstract Number: 1484

B Cell Intracellular IFNβ as a Unique Cellular Marker for the Development of Lupus Nephritis

8:30AM-10:30AM: Abstract Number: 1483

Down-regulation of Hematopoietic Progenitor Kinase 1 by Aberrant Epigenetic Alterations in T Follicular Helper Cells Accounts for Excessive Immunity in Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 1500

Expression of Neuropilin-1 Is Significantly Increased in Dendritic Cells and CD4 + T Cells and It Correlates Disease Activity in the Patients with Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 1494

Functional Effects of a Lupus-associated PRKG1 Variant on the RhoA-ROCK Pathway and Response to Type I Interferon

8:30AM-10:30AM: Abstract Number: 1485

Glycosphingolipids: Potential Urine Biomarkers of Therapeutic Response in Lupus Nephritis

8:30AM-10:30AM: Abstract Number: 1489

Identification of Mitochondrial Antigens Targeted by Autoantibodies in Systemic Lupus Erythematosus (SLE)

8:30AM-10:30AM: Abstract Number: 1499

Imbalance Between T Follicular Cells and T Regulatory Cells Involved in High Fat-Diet Associated Lupus Development in MRL/lpr Mice

8:30AM-10:30AM: Abstract Number: 1505

Inflammatory Dendritic Cell and Th17 Polarization in Mouse Model of Lupus Nephritis

8:30AM-10:30AM: Abstract Number: 1497

Kidney Disease in Lupus Patients Is Linked to Monocytes’ Aberrant Spliceosome and Altered Expression of IFN-Response Related Genes

8:30AM-10:30AM: Abstract Number: 1482

LN Urinary Proteomics Reveals Common Biological Pathways Identified by Distinct Disease Measures

8:30AM-10:30AM: Abstract Number: 1480

LncRNA XIST Alters the Balance of Peripheral Blood Immune Cells in Systemic Lupus Erythematosus by Regulating the miR-17-92/OFLM4 and CEACAM8 Axis

8:30AM-10:30AM: Abstract Number: 1502

Longitudinal Changes in B Cell Subsets in Patients in the Mesenchymal Stromal Cell Trial in Lupus: Analysis of the First Cohort

8:30AM-10:30AM: Abstract Number: 1481

Malondialdehyde-acetaldehyde Antibodies Occur in Systemic Lupus Erythematosus and Associate Specifically with Neuropsychiatric Involvement

8:30AM-10:30AM: Abstract Number: 1488

Metabolic Alterations of Systemic Lupus Erythematosus NK Cells Determine Response to Anti-CD38 and Anti-SLAMF7 Monoclonal Antibodies

8:30AM-10:30AM: Abstract Number: 1501

Molecular Modelling Predicts Inhibition of Functional Effects of Anti-thrombin III on Factor Xa Mediated Complement Activation by Anti- Factor Xa IgG in SLE and APS

8:30AM-10:30AM: Abstract Number: 1495

Multiplexed Profiling of Treatment Naïve Cutaneous Lupus Skin Stratified by Patient Response to Antimalarials

8:30AM-10:30AM: Abstract Number: 1490

Myeloid and B Cell Transcriptional Phenotypes Reveal Race Dependent Differences in Early Autoimmunity

8:30AM-10:30AM: Abstract Number: 1498

Platelet Secreted LGALS3BP Induces a Pro-inflammatory Phenotype in Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 1503

Putting the Pieces on the Board: Mapping SLE Nephritis Biopsies from the Accelerating Medicines Project Using High-Density Immunofluorescence Imaging

8:30AM-10:30AM: Abstract Number: 1491

Single-cell Analysis of Paired Skin and Blood Samples from Patients with SLE and Cutaneous Lupus Suggests CD16+ DCs Arise from Non-classical Monocytes That Enter Nonlesional Skin, Undergo Type I IFN Education, and Engage in Extensive Crosstalk with Diverse Immune and Stromal Cell Types

8:30AM-10:30AM: Abstract Number: 1506

SLAMF6 Compartmentalization Regulates Autoimmune T Cell Responses

8:30AM-10:30AM: Abstract Number: 1487

Type I Interferon Modulates Langerhans Cell ADAM17 in Lupus to Contribute to Photosensitivity

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].